Herpes zoster: Focus on treatment in older adults

Antiviral Research

Volumn 44, Issue 3, 1999, Pages 145-154

  Whitley, Richard J ^a   Gnann, John W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Elderly; Herpes viruses; Treatment; Zoster

Indexed keywords

ACICLOVIR; FAMCICLOVIR; PENCICLOVIR; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ADULT; AGED; DISEASE COURSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; HERPES ZOSTER; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW;

AGED; ANTIVIRAL AGENTS; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPETENCE;

EID: 0033380510     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00064-9     Document Type: Review

References (47)

1. Ashton R.E. Efficacy of Once and Twice Daily Famciclovir in the Treatment of Acute Zoster. 1996;European Congress of Chemotherapy, Glasgow, Scotland.
2. Balfour H.H. Jr Antiviral drugs. N. Engl. J. Med. 340:1999;1255-1268.
3. Beutner K.R., Friedman D.J., Forszpaniak C., Andersen P.L., Wood M.J. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother. 39:1995;1547-1553.
4. Boyd M.R., Bacon T.H., Sutton D., Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl) guanine (BRL 39123) in cell structure. Antimicrob. Agents Chemother. 31:1987;1238-1242.
5. Boyd M.R., Safrin S., Kern E.R. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antivir. Chem. Chemother. 4(Suppl. 1):1993;3-11.
6. Burke B.L., Steele R.W., Beard O.W., Woods J.S., Cain T.D., Marmer D.J. Immune response to varicella-zoster in the aged. Arch. Intern. Med. 142:1982;291-293.
7. Choo P.W., Donahue J.G., Manson J.E., Plott R. The epidemiology of varicella and its complications. J. Infect. Dis. 172:1995;706-712.
8. Cobo L.M., Foulks G.N., Liesegang T. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 93:1986;763-770.
9. Cohen J.I., Brunell P.A., Straus S.E., Krause P.R. Recent advances in varicella-zoster virus infection. Ann. Intern. Med. 130:1999;922-932.
10. Collins P., Bauer D.J. The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl) guanine (acycloguanosine), a new antiviral agent. J. Antimicrob. Chemother. 5:1979;432-436.
11. de Greef, H., Famciclovir Herpes Zoster Clinical Study Group, 1994. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int. J. Antimicrob. Agents 4, 241-246.
12. de Miranda P., Blum M.R. Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother. 12:1983;29-37.
13. Derse D., Chang Y.-C., Furman P.A., Elion G.B. Inhibition of purified human and herpes simplex virus-induced DNA polymerase by 9-(2-hydroxyethoxy methyl)guanine [acyclovir] triphosphate: effect on primer-template function. J. Biol. Chem. 256:1981;11447-11451.
14. Donahue J.G., Choo P.W., Manson J.E., Plat R. The incidence of herpes zoster. Arch. Intern. Med. 155:1995;1605-1609.
15. Dworkin R.H., Carrington D., Cunningham A., Kost R.G., Levin J.J., McKendrick M.W., Oxman M.N., Rentier B., Schmader K.E., Tappeiner G., Wassilew S.W., Whitely R.J. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Res. 33:1997;73-85.
16. Dworkin R.H., Portenoy R.K. Pain and its persistence in herpes zoster. Pain. 67:1996;241-251.
17. Earnshaw D.L., Bacon T.H., Darlison S.J., Edmonds K., Perkins R.M., Vere Hodge R.A. Mode of antiviral action on penciclovir in MRC-5 cells infected with herpes simplex virus type 1, HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 36:1992;2747-2757.
18. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., Schaffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. USA. 74:1977;5716-5720.
19. Fowles S.E., Pierce D.M., Prince W.T. The tolerance to and pharmacokinets of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur. J. Clin. Pharmacol. 43:1992;513-516.
20. Furman P.A., St. Clair M.H., Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J. Biol. Chem. 259:1984;9575-9579.
21. Fyfe J.A., Keller P.M., Furman P.A., Miller R.A., Elion G.B. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J. Biol. Chem. 253:1978;8721-8727.
22. Harding S.P., Porter S.M. Oral acyclovir in herpes zoster ophthalmicus. Curr. Eye Res. 10:1991;177-182.
23. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Med. 58:1965;9-20.
24. Huff J.C., Bean B., Balfour H.H. Jr, Laskin O.L., Connor J.D., Corey L., Bryson Y.J., McGuirt P.W. Therapy of herpes zoster with oral acyclovir. Am. J. Med. 85:1988;84-89.
25. Jackson J.L., Gibbons R., Meyer G., Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. Arch. Intern. Med. 157:1997;909-912.
26. Kost R.G., Straus S.E. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N. Engl. J. Med. 335:1996;32-42.
27. Laskin O.L. Acyclovir: pharmacology and clinical experience. Arch. Intern. Med. 144:1984;1241-1246.
28. Levin M.J., Murray M., Zerbe G.O., White C.J., Hayward A.R. Immune response of elderly persons 4 years after receiving a live attentuated varicella vaccine. J. Infect. Dis. 170:1994;522-526.
29. Meier J.L., Straus S.E. Comparative biology of latent varicellal-zoster virus and herpes simplex virus infections. J. Infect. Dis. 166:1992;S13-S23.
30. Morton P., Thomson A.N. Oral acyclovir in the treatment of herpes zoster in general practice. N. Z. Med. J. 102:1989;93-95.
31. Perry C.M., Faulds D. Valaciclovir: a review of its antiviral, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs. 52:1996;754-772.
32. Pue M.A., Benet L.Z. Pharmacokinetics of famciclovir. Antivir. Chem. Chemother. 4(Suppl. 1):1993;47-56.
33. Pue M.A., Pratt S.K., Fairless A.J., Fowles S., Laroche J., Georgiou P., Prince W. Linear pharmacokinetcs of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J. Antimicrob. Chemother. 33:1994;119-127.
34. Ragozzino M.W., Melton L.J. III, Kurland L.T., Chu C.P., Perry H.O. Populations-based study of herpes zoster and its sequelae. Medicine. 61:1982;310-316.
35. Rowbotham M., Harden N., Stacey B., Bernstein P., Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial. J. Am. Med. Assoc. 280:1998;1837-1842.
36. Schaeffer H.J., Beauchamp L., deMiranda P., Elion G.B., Bauer D.J., Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature. 272:1978;583-585.
37. Soul-Lawton J., Seaber E., On N., Wootton R., Rolan P., Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 39:1995;2759-2764.
38. Tyring, S., Barbarash, R.A., Nahlik, J.E., Cunningham, A., Marley, J., Heng, M., Jones, T., Rea, T., Boon, R., Saltzman, R., Collaborative Famciclovir Herpes Zoster Study Group, 1995. Famciclovir for the treatment of acute herpes zoster. Effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123, 89-96.
39. Vere Hodge R.A. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antivir. Chem. Chemother. 4:1993;67-84.
40. Watson C.P.N., Chipman M., Reed K., Evans R.J., Birkett N. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. Pain. 48:1992;29-36.
41. Weller S., Blum R., Doucette M., Burnette T., Cederberg D.M., de Miranda P. et al. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54:1993;595-605.
42. Whitley R.J., Shukla S., Crooks R.J. The identification of risk factors associated with persistent pain following herpes zoster. J. Infect. Dis. 178(Suppl. 1):1998;S71-S75.
43. Whitley, R.J., Weiss, H., Gnann, J.W., Tyring, S., Mertz, G.J., Pappas, P., Schleupner, C.C., Hayden, F., Wolf, J., Soong, S.-J., National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, 1996. A randomized, placebo-controlled trial of acyclovir with and without steroids for the treatment of herpes zoster. Ann. Intern. Med. 125, 376-383.
44. Whitley R.J., Weiss H.L., Soong S.J., Gnann J.W. Herpes zoster: risk categories for persistent pain. J. Infect. Dis. 179:1999;9-15.
45. Wood M.J., Johnson R.W., McKendrick M.W., Taylor J., Mandal B.K., Crooks J. A randomized trial of acyclovir for 7 or 21 days with and without prednisolone for treatment of acute herpes zoster. N. Engl. J. Med. 330:1994;896-900.
46. Wood M.J., Kay R., Dworkin R.H., Soong S.-J., Whitley R.J. Oral acyclovir accelerates pain resolution in herpes zoster: a meta-analysis of placebo-controlled trials. Clin. Infect. Dis. 22:1996;341-347.
47. Wood M.J., Ogan P.H., McKendrick M.W., Care C.D., McGill J.I., Webb E.M. Efficacy of oral acyclovir treatment of acute herpes zoster. Am. J. Med. 85:1988;79-83.